Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze

Peptides

Volumn 21, Issue 1, 2000, Pages 37-44

  Britton, Karen T ^a   Akwa, Yvette ^b   Spina, Mariarosa G ^b   Koob, George F ^b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Anxiety; Conflict test; Corticotropin releasing factor; Elevated plus maze; Neuropeptide Y

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; NEUROPEPTIDE Y;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; INSTRUMENTAL CONDITIONING; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; STRESS; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY; CONFLICT (PSYCHOLOGY); CORTICOTROPIN-RELEASING HORMONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; INJECTIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; NEUROPEPTIDE Y; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR;

ANIMALIA;

EID: 0033998014     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(99)00169-2     Document Type: Article

References (54)

1. Aoki C., Pickel V. Neuropeptide Y in the cerebral cortex and caudate-putamen nuclei ultrastructural basis for interactions with GABAergic and non-GABAergic neurons . J Neurosci. 9:1989;4333-4354.
2. Baldwin H.A., Rassnick S., Rivier J., Koob G.F., Britton K.T. CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology. 103:1991;227-232.
3. Britton K.T., Morgan J., Rivier J., Koob G.F. Chlordiazepoxide attenuates CRF-induced response suppression in the conflict test. Psychopharmacology. 86:1985;170-174.
4. Britton K.T., Lee G., Rivier J., Koob G.F. Corticotropin releasing factor (CRF) receptor antagonist blocks activation and "anxiogenic" actions of CRF in the rat. Brain Res. 369:1986;303-306.
5. Britton K.T., Lee G., Koob G.F. Corticotropin releasing factor and amphetamine exaggerate partial agonist properties of benzodiazepine antagonist Ro 15-1788 in the conflict test. Psychopharmacology. 94:1988;306-311.
6. Britton K.T., Southerland S., Van Uden E., Kirby D., Rivier J., Koob G.F. Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology. 132:1997;6-13.
7. Broqua P., Wettstein J.G., Rocher M.N., Gauthier-Martin B., Junien J.L. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav Pharmacol. 6:1995;215-222.
8. Castagne V., Corder R., Gaillard R., Mormede P. Stress-induced changes in circulating neuropeptide Y in the rat comparison with catecholamines . Regul Pept. 19:1987;55-63.
9. Chen S.-W., Rodriguez L., Davies M.F., Loew G.H. The hyperphagic effect of 3α- hydroxylated pregnane steroids in male rats. Phamacol Biochem Behav. 53:1996;777-782.
10. Cheng J.-T., Chen C.-F., Shum A., Wang J.-Y., Chen H. Increase of plasma neuropeptide Y-like immunoreactivity following chronic hypoxia in the rat. Neurosci Lett. 140:1992;211-214.
11. Colmers W.F., Klapstein G., Fournier A., St-Pierre S., Treherne K. Presynaptic inhibition by Neuropeptide Y in rat hippocampal slices in vitro is mediated by a Y2 receptor. Br J Pharmacol. 102:1991;41-44.
12. De Souza E.B. Corticotropin-releasing factor receptors in the rat central nervous system characterization and regional distribution . J Neurosci. 7:1987;88-100.
13. Ehlers C.L., Somes C., Lopez A., Kirby D., Rivier J.E. Electrophysiological actions of neuropeptide Y and its analogs new measures for anxiolytic therapy? Neuropsychopharmacology. 17:1997;34-43.
14. Ericson J., Clegg K., Palmiter R. Sensitivity and susceptibility to seizures of mice lacking neuropeptide Y. Nature. 381:1996;415-418.
15. Fuxe K., Agnati L., Harfstrand A., Zini I., Tatemoto K., Pich E., Hokfelt V., Mutt V., Terenius L. Central administration of neuropeptide Y induces hypotension, bradypnea and EEG synchronization in the rat. Acta Physiol Scand. 118:1983;189-192.
16. Gehlert D.R. Subtypes of receptors for neuropeptide Y implications for the targeting of therapeutics . Life Sci. 55:1994;551-562.
17. Gray R.W., Cooper S.J. Benzodiazepines and palatability taste reactivity in normal ingestion . Physiol Behav. 58:1995;853-859.
18. Gray T.S., Morley J.E. Neuropeptide Y anatomical distribution and possible function in mammalian nervous system . Life Sci. 38:1986;389-401.
19. Gue M., Junien J., Del Rio C., Bueno L. Neuropeptide Y and sigma ligand (JO 1784) suppress stress-induced colonic motor disturbances through sigma and cholecystokinin receptors. J Pharmacol Exp Ther. 261:1992;850-855.
20. Gue M., Junien J., Reeve J., Rivier J., Grandt D., Tache Y. Reversal by NPY, PYY, and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats. Br J Pharmacol. 118:1996;237-242.
21. Gustafson E.L., Card J.P., Moore R.Y. Neuropeptide Y localization in the rat amygdaloid complex. J Comp Neurol. 251:1986;349-362.
22. Haas D.A., George S.R. Neuropeptide Y administration acutely increases hypothalamic corticotropin-releasing factor immunoreactivity. Life Sci. 41:1987;2725-2731.
23. Heilig M., Murrison R. Intracerebroventricular neuropeptide Y protects against stress-induced gastric erosions in the rat. Eur J Pharmacol. 137:1987;127-129.
24. Heilig M., Soderpalm B., Engel J., Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology. 94:1989;524-529.
25. Heilig M., Koob G.F., Britton K.T. Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides, in an operant conflict test. Regul Pept. 41:1992;65-69.
26. Heilig M., McLeod S., Brot M., Heinrichs S.C., Menzaghi F., Koob G.F., Britton K.T. Anxiolytic-like action of neuropeptide Y mediation by Y1 receptors in the amygdala, and dissociation from food effects . Neuropsychopharmacology. 98:1993;357-363.
27. Heilig M., Koob G.F., Ekman R., Britton K.T. Corticotropin-releasing factor and neuropeptide Y role in emotional integration . Trends Neurosci. 17:1994;80-85.
28. Heilig M. Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic actions of NPY in amygdala and paradoxically increases feeding. Regul Pept. 59:1995;201-205.
29. Heinrichs S.C., Pich E.M., Britton K.T., Koob G.F. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res. 581:1992;190-197.
30. Heinrichs S.C., Menzaghi F., Pich M., Hauger R., Koob G.F. Corticotropin-releasing factor in the paraventricular nucleus modulates feeding induced by NPY. Brain Res. 611:1993;18-24.
31. Jimenez M., Bueno L. Inhibitory effects of neuropeptide Y (NPY) on CRF- and stress-induced cecal motor response in rats. Life Sciences. 47:1990;205-211.
32. i protein to block the psychological stress and corticotropin-releasing factor-induced colonic motor activation in rats. Neuropharmacology. 30:1991;1119-1121.
33. Kalin N.H., Sherman J., Takahashi L. Antagonism of endogenous CRH systems attenuates stress-induced freezing behavior in rats. Brain Res. 457:1988;130-135.
34. Liang K.C., Melia K., Miserendino M., Falls W., Campeau S., Davis M. Corticotropin-releasing factor long lasting facilitation of the acoustic startle reflex . J Neurosci. 12:1992;2303-2312.
35. Lundberg J., Martinsson A., Hemsen A., Theodorsson-Norheim E., Scendenhag J., Ekblom B., Hjemdahl P. Co-release of neuropeptide Y and catecholamines during physical exercise in man. Biochem Biophys Res Comm. 133:1985;30-36.
36. McDonald A.J., Pearson J.C. Coexistence of GABA and peptide immunoreactivity in non-pyramidal neurons of the basolateral amygdala. Neurosci Lett. 100:1989;53-58.
37. Massari V., Chan J., Chronwall B., O'Donohue T., Pickel V. Neuropeptide Y in the rat nucleus accumbens ultrastructure, localization, and synaptic interaction with GABAergic neurons . J Neurosci Res. 19:1988;171-186.
38. Menzaghi F., Howard R., Heinrichs S., Vale W., Rivier J., Koob G.F. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J Pharmacol Exp Ther. 269:1994;562-572.
39. Morley J.E., Levine A., Gosnell B., Kneip J., Grace M. Effects of neuropeptide Y on ingestive behaviors in the rat. Am J Physiol. 252:1987;R599-R609.
40. Morris M., Kapoor V., Chalmers J. Plasma neuropeptide Y concentration is increased after hemorrhage in conscious rats relative contributions of sympathetic nerves and adrenal medulla . J Cardiol Pharmacol. 9:1987;541-545.
41. Smith M.A., Weiss S.R.B., Berry R.L., Zhang Z.-X., Clark M., Massenburg G., Post R.M. Amygdala-kindled seizures increase the expression of corticoptropin-releasing factor (CRF) and CRF-binding protein in GABAergic interneurons of the dentate gyrus. Brain Res. 745:1997;248-256.
42. Pollard G.T., Howard J.L. Comparison of chlordiazepoxide and food deprivation on punished and unpunished responding maintained by food. Exp Clin Psychopharmacol. 2:1994;37-42.
43. Sperk G., Marksteiner J., Gruber B., Bellman R., Mahata M., Ortler M. Functional changes in neuropeptide Y- and somatostatin-containing neurons induced by limbic seizures in the rat. Neuroscience. 50:1992;831-846.
44. Swerdlow N.E., Geyer M., Vale W., Koob G.F. Corticotropin-releasing factor potentiates startle reflex in rats blockade by chlordiazepoxide . Psychopharmacology. 88:1986;142-152.
45. 9-41. Neuropsychopharmacology. 2:1989;285-292.
46. Tizabi Y., Calogero A. Effects of various neurotransmitters on the release of corticotropin releasing hormone from the rat cortex in vitro. Synapse. 10:1992;341-348.
47. Wan C.P., Lau B.H.S. Neuropeptide Y receptor subtype. Life Sci. 56:1995;1055-1064.
48. Yamada K., Shibasaki T., Ysumori C., Imaki T., Hotta M., Wakabayashi I., Demura H. Neuropeptide Y reverses corticotropin-releasing hormone- and psychological stress-caused shortening of sodium pentobarbital-induced sleep in rats. Brain Res. 725:1996;272-275.
49. Wahlestedt C., Pich E., Koob G.F., Yee F., Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science. 259:1993;528-530.
50. Wahlestedt C., Reis D.J. Neuropeptide Y-related peptides and their receptors - are the receptors potential therapeutic drug targets? Annu Rev Pharmacol Toxicol. 32:1993;309-352.
51. Wettstein J.G., Broqua P., Rocher M.N., Junien J.L. Attenuation of fear-potentiated startle by neuropeptide Y receptor agonists. Neuropeptides. 26:1994;116-117.
52. White JD. Neuropeptide Y: a central regulator of energy homeostasis. Reg. Peptides 1993;49:93-10.
53. Zukowska-Grojec Z., Shen Z., Capraro P., Vaz C. Cardiovascular, neuropeptide Y, and adrenergic responses to stress are sexually differentiated. Physiol Behav. 49:1991;771-777.
54. 1 receptors. Am J Physiol. 270:1996;H796-H800.